Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to adults with advanced solid tumors.

Official Title

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Subject has histologically confirmed malignancy that is metastatic or unresectable - Subject has disease that is assessable by tumor marker, physical, or radiologic means - Subject is at least 18 years old - Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%) - Subject has a life expectancy ≥ 3 months - Subject has normal organ and marrow function - Subject gives written informed consent - Subject must use an accepted method of contraception during the study - Female subjects of childbearing potential must have a negative pregnancy test
Exclusion Criteria:
  1. - Subject has received anticancer treatment within 30 days of first dose of XL647 - Subject has received another investigational agent within 30 days of first dose of XL647 - Subject has known brain metastases - Subject has corrected QT interval (QTc) of > 0.45 seconds - Subject is currently receiving anticoagulation therapy with warfarin - Subject has uncontrolled intercurrent illness - Subject is pregnant or breastfeeding - Subject has known HIV


Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.


Joanne Fehling